<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03017573</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2016-03</org_study_id>
    <nct_id>NCT03017573</nct_id>
  </id_info>
  <brief_title>Prospective Biobanking Study in Ovarian, Breast and Head and Neck Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)</brief_title>
  <acronym>SCANDARE</acronym>
  <official_title>Prospective Biobanking Study in Ovarian, Breast and Head and Neck Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SCANDARE is a prospective biobanking study on tumor (+/- nodes), plasma and blood samples at&#xD;
      different time points in ovarian, triple negative breast and head and neck cancer patients.&#xD;
      This study will allowed to identify new molecular and/or immunological biomarkers associated&#xD;
      with clinical and biological features of the tumors. All patients will receive standard&#xD;
      treatment according to the stage of the diseases and usual procédures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will have blood and +/- tumor samples at the following times :&#xD;
&#xD;
        1. if eligible for surgery :&#xD;
&#xD;
             -  at surgery (blood + tumor and nodes)&#xD;
&#xD;
             -  after surgery (blood)&#xD;
&#xD;
             -  before cycle 1 of adjuvant chemotherapy or before radiotherapy (blood + tumor&#xD;
                biopsie and nodes if possible)&#xD;
&#xD;
             -  before cycle 2 of adjuvant chemotherapy or after radiotherapy (blood)&#xD;
&#xD;
             -  at progression (blood + tumor biopsie and nodes if possible)&#xD;
&#xD;
        2. if eligible for neoadjuvant chemotherapy :&#xD;
&#xD;
             -  before neoadjuvant therapy (blood + tumor biopsie and nodes)&#xD;
&#xD;
             -  during neoadjuvant therapy (post cycle 1) (blood)&#xD;
&#xD;
             -  at the time of surgery (blood + tumor and nodes)&#xD;
&#xD;
             -  before cycle 1 of adjuvant chemotherapy or before radiotherapy (blood + tumor&#xD;
                biopsie and nodes)&#xD;
&#xD;
             -  before cycle 2 of adjuvant chemotherapy or after radiotherapy (blood)&#xD;
&#xD;
             -  at progression (blood + tumor biopsie and nodes)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2017</start_date>
  <completion_date type="Anticipated">February 2026</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between tumor molecular/immunological profile and Baseline clinicobiological features</measure>
    <time_frame>up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between disease recurrence and molecular and/or immunological biomarkers</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between genomic alterations and immune parameters</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between mutations load and immune parameters</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between ctDNA levels, de novo mutations in ctDNA and immune</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Triple-Negative Breast Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Tumor and blood sampling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will have a biopsy or a surgery and blood sampling at different time points.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor biopsies / Tumor surgery</intervention_name>
    <description>Tumoral tissues samples must be collected at different times points :&#xD;
at the time of surgery&#xD;
before first cycle of adjuvant treatment (if possible)&#xD;
at progression (if possible)&#xD;
OR&#xD;
before neoadjuvant therapy&#xD;
at the time of surgery&#xD;
before first cycle of adjuvant treatment (if possible)&#xD;
at progression (if possible)</description>
    <arm_group_label>Tumor and blood sampling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood withdrawal</intervention_name>
    <description>Blood samples must be collected at different times points :&#xD;
at the time of surgery&#xD;
after surgery&#xD;
before first cycle of adjuvant treatment or before radiotherapy&#xD;
before second cycle of adjuvant treatment or after radiotherapy&#xD;
at progression&#xD;
OR&#xD;
before neoadjuvant therapy&#xD;
during neoadjuvant therapy (post cycle 1)&#xD;
at the time of surgery&#xD;
before first cycle of adjuvant treatment or before radiotherapy&#xD;
before second cycle of adjuvant treatment or after radiotherapy&#xD;
at progression</description>
    <arm_group_label>Tumor and blood sampling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Tumor types :&#xD;
&#xD;
               1. Newly diagnosed treatment-naïve ovarian cancer patients eligible for surgery or&#xD;
                  neoadjuvant chemotherapy&#xD;
&#xD;
               2. Newly diagnosed treatment-naïve triple-negative breast cancer patients eligible&#xD;
                  for surgery or neoadjuvant chemotherapy&#xD;
&#xD;
               3. Newly diagnosed treatment-naïve head and neck cancer patients eligible for&#xD;
                  surgery&#xD;
&#xD;
          2. Male or female patients ≥ 18 years of age&#xD;
&#xD;
          3. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Male or female patients ≤18 years old&#xD;
&#xD;
          2. Patients with any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          3. Individually deprived of liberty or placed under the authority of a tutor&#xD;
&#xD;
          4. Patients not affiliated to the Social Security System&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe LE TOURNEAU, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Sophie PLISSONNIER</last_name>
    <phone>01 56 24 57 65</phone>
    <email>drci.promotion@curie.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe LE TOURNEAU, MD</last_name>
      <email>christophe.letourneau@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe LE TOURNEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie Hopital Rene Huguenin</name>
      <address>
        <city>Saint-cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas POUGET, MD</last_name>
      <email>nicolas.pouget@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas POUGET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 9, 2017</study_first_submitted>
  <study_first_submitted_qc>January 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2017</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunological biomarkers</keyword>
  <keyword>molecular profil</keyword>
  <keyword>Circulating tumor DNA (ctDNA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

